Femasys is trading 6.6% down at $3.73 as part of a broader risk-off move affecting biotech and small-cap healthcare stocks.
- The decline occurs without fresh company-specific news, following a period of volatility and historical concerns regarding dilution.
- Broader market pressure is evident as the SPDR S&P Biotech ETF and major indices trade lower, indicating sector-wide and macroeconomic headwinds.